Expanding the clinical and molecular spectrum of ATP6V1A related metabolic cutis laxa.


Journal

Journal of inherited metabolic disease
ISSN: 1573-2665
Titre abrégé: J Inherit Metab Dis
Pays: United States
ID NLM: 7910918

Informations de publication

Date de publication:
07 2021
Historique:
revised: 08 12 2020
received: 18 08 2020
accepted: 14 12 2020
pubmed: 16 12 2020
medline: 18 1 2022
entrez: 15 12 2020
Statut: ppublish

Résumé

Several inborn errors of metabolism show cutis laxa as a highly recognizable feature. One group of these metabolic cutis laxa conditions is autosomal recessive cutis laxa type 2 caused by defects in v-ATPase components or the mitochondrial proline cycle. Besides cutis laxa, muscular hypotonia and cardiac abnormalities are hallmarks of autosomal recessive cutis laxa type 2D (ARCL2D) due to pathogenic variants in ATP6V1A encoding subunit A of the v-ATPase. Here, we report on three affected individuals from two families with ARCL2D in whom we performed whole exome and Sanger sequencing. We performed functional studies in fibroblasts from one individual, summarized all known probands' clinical, molecular, and biochemical features and compared them, also to other metabolic forms of cutis laxa. We identified novel missense and the first nonsense variant strongly affecting ATP6V1A expression. All six ARCL2D affected individuals show equally severe cutis laxa and dysmorphism at birth. While for one no information was available, two died in infancy and three are now adolescents with mild or absent intellectual disability. Muscular weakness, ptosis, contractures, and elevated muscle enzymes indicated a persistent myopathy. In cellular studies, a fragmented Golgi compartment, a delayed Brefeldin A-induced retrograde transport and glycosylation abnormalities were present in fibroblasts from two individuals. This is the second and confirmatory report on pathogenic variants in ATP6V1A as the cause of this extremely rare condition and the first to describe a nonsense allele. Our data highlight the tremendous clinical variability of ATP6V1A related phenotypes even within the same family.

Identifiants

pubmed: 33320377
doi: 10.1002/jimd.12341
pmc: PMC8638669
doi:

Substances chimiques

ATP6V1A protein, human EC 3.6.1.-
Vacuolar Proton-Translocating ATPases EC 3.6.1.-

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

972-986

Subventions

Organisme : NHGRI NIH HHS
ID : UM1 HG008900
Pays : United States
Organisme : Medical Research Council
ID : MR/N010035/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1000848
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N025431/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N025431/1
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/V009346/1
Pays : United Kingdom
Organisme : CIHR
ID : FDN-167281
Pays : Canada

Informations de copyright

© 2020 The Authors. Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM.

Références

Hum Genet. 2016 May;135(5):525-540
pubmed: 27023906
Nat Rev Mol Cell Biol. 2007 Nov;8(11):917-29
pubmed: 17912264
Nat Genet. 2009 Sep;41(9):1016-21
pubmed: 19648921
Eur J Hum Genet. 2005 Apr;13(4):414-21
pubmed: 15657616
Nat Genet. 2000 Jul;25(3):343-6
pubmed: 10888887
Nat Genet. 2000 Sep;26(1):71-5
pubmed: 10973252
Eur J Hum Genet. 2014 Jul;22(7):888-95
pubmed: 23963297
Neurology. 2009 Oct 6;73(14):1164; author reply 1164-5
pubmed: 19805737
J Inherit Metab Dis. 2020 Nov;43(6):1382-1391
pubmed: 32418222
Am J Hum Genet. 2015 Sep 3;97(3):483-92
pubmed: 26320891
Hum Genet. 2012 Nov;131(11):1761-73
pubmed: 22773132
Nat Genet. 2008 Jan;40(1):32-4
pubmed: 18157129
Brain. 2018 Jun 1;141(6):1703-1718
pubmed: 29668857
Am J Hum Genet. 2017 Feb 2;100(2):216-227
pubmed: 28065471
Hum Mutat. 2019 Aug;40(8):1030-1038
pubmed: 31116477
Methods Mol Biol. 2020;2169:197-216
pubmed: 32548831
Chem Commun (Camb). 2016 Feb 7;52(11):2318-21
pubmed: 26727964
Hum Mutat. 2020 Sep;41(9):1600-1614
pubmed: 32516863
J Exp Med. 2017 Dec 4;214(12):3707-3729
pubmed: 29127204
Chem Commun (Camb). 2013 Dec 14;49(96):11293-5
pubmed: 24153356
J Inherit Metab Dis. 2021 Jul;44(4):972-986
pubmed: 33320377
Bioinformatics. 2014 Sep 1;30(17):2503-5
pubmed: 24812344
Science. 2020 Mar 20;367(6484):1366-1371
pubmed: 32193326
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Eur J Hum Genet. 2018 May;26(5):618-621
pubmed: 29192153
Nucleic Acids Res. 2020 Jul 2;48(W1):W162-W169
pubmed: 32338743
Am J Med Genet A. 2014 Apr;164A(4):1049-55
pubmed: 24459010
Nat Methods. 2014 Apr;11(4):361-2
pubmed: 24681721
Nucleic Acids Res. 2019 Jul 2;47(W1):W114-W120
pubmed: 31106342
Science. 2020 Mar 13;367(6483):1240-1246
pubmed: 32165585
Nat Genet. 1994 Oct;8(2):195-202
pubmed: 7842019
Curr Protoc Hum Genet. 2013 Jan;Chapter 7:Unit7.20
pubmed: 23315928
Hum Mol Genet. 2000 Nov 22;9(19):2853-8
pubmed: 11092761

Auteurs

Guido Vogt (G)

Institut für Medizinische Genetik und Humangenetik, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Max Planck Institute for Molecular Genetics, RG Development & Disease, Berlin, Germany.

Naji El Choubassi (N)

Institut für Medizinische Genetik und Humangenetik, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Max Planck Institute for Molecular Genetics, RG Development & Disease, Berlin, Germany.

Ágnes Herczegfalvi (Á)

Department of Pediatric Neurology, Semmelweis Medical University, II. Pediatric Clinic, Budapest, Hungary.

Heike Kölbel (H)

Department of Pediatric Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Anja Lekaj (A)

Institut für Medizinische Genetik und Humangenetik, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Ulrike Schara (U)

Department of Pediatric Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Manuel Holtgrewe (M)

CUBI - Core Unit Bioinformatics, Berlin Institute of Health, Berlin, Germany.

Sabine Krause (S)

Friedrich-Baur-Institute, Department of Neurology, Ludwig-Maximilians-University of Munich, Munich, Germany.

Rita Horvath (R)

Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.

Markus Schuelke (M)

Department of Neuropediatrics, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Christoph Hübner (C)

Department of Neuropediatrics, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Stefan Mundlos (S)

Institut für Medizinische Genetik und Humangenetik, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Max Planck Institute for Molecular Genetics, RG Development & Disease, Berlin, Germany.

Andreas Roos (A)

Department of Pediatric Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Ontario, Canada.

Hanns Lochmüller (H)

Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
Division of Neurology, Department of Medicine, The Ottawa Hospital, Ottawa, Canada.
Brain and Mind Research Institute, University of Ottawa, Ottawa, Canada.

Veronika Karcagi (V)

NIEH, Department of Molecular Genetics and Diagnostics, Budapest, Hungary.
Istenhegyi Genetic Diagnostic Centre, Budapest, Hungary.

Uwe Kornak (U)

Institut für Medizinische Genetik und Humangenetik, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Max Planck Institute for Molecular Genetics, RG Development & Disease, Berlin, Germany.
Institute of Human Genetics, University Medical Center Göttingen, Göttingen, Germany.

Björn Fischer-Zirnsak (B)

Institut für Medizinische Genetik und Humangenetik, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Max Planck Institute for Molecular Genetics, RG Development & Disease, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH